NO20044571L - Isokinolinderivater - Google Patents
IsokinolinderivaterInfo
- Publication number
- NO20044571L NO20044571L NO20044571A NO20044571A NO20044571L NO 20044571 L NO20044571 L NO 20044571L NO 20044571 A NO20044571 A NO 20044571A NO 20044571 A NO20044571 A NO 20044571A NO 20044571 L NO20044571 L NO 20044571L
- Authority
- NO
- Norway
- Prior art keywords
- well
- medicaments
- isoquinoline
- relates
- isoquinolino
- Prior art date
Links
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 2
- 239000003814 drug Substances 0.000 abstract 2
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract 1
- 108010062431 Monoamine oxidase Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår isokinolino derivater med den generelle formel. hvor Y er >C=0 eller -CH-, Z er >C=0 eller -CH- og R, R2 og m er som definert i beskrivelsen, så vel som deres farmasøytisk akseptable salter. Oppfinnelsen angår videre medikamenter inneholdende disse forbindelser, en fremgangsmåte for deres preparation så vel som anvendelse av dem for fremstilling av medikamenter for behandling eller forebygging av sykdommer hvor MAO-B inhibitorer might være fordelaktig.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02009253 | 2002-04-26 | ||
PCT/EP2003/003845 WO2003091219A1 (en) | 2002-04-26 | 2003-04-14 | Isoquinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20044571L true NO20044571L (no) | 2004-10-22 |
Family
ID=29265896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20044571A NO20044571L (no) | 2002-04-26 | 2004-10-22 | Isokinolinderivater |
Country Status (31)
Country | Link |
---|---|
US (1) | US6818774B2 (no) |
EP (1) | EP1501804B1 (no) |
JP (1) | JP4322685B2 (no) |
KR (1) | KR100681585B1 (no) |
CN (1) | CN1310890C (no) |
AR (1) | AR039651A1 (no) |
AT (1) | ATE440821T1 (no) |
AU (1) | AU2003227614B2 (no) |
BR (1) | BR0309562A (no) |
CA (1) | CA2483461C (no) |
DE (1) | DE60328978D1 (no) |
DK (1) | DK1501804T3 (no) |
ES (1) | ES2329354T3 (no) |
GT (1) | GT200300095A (no) |
HK (1) | HK1080836A1 (no) |
HR (1) | HRP20040952A2 (no) |
IL (1) | IL164677A0 (no) |
MX (1) | MXPA04010537A (no) |
MY (1) | MY133527A (no) |
NO (1) | NO20044571L (no) |
NZ (1) | NZ535885A (no) |
PA (1) | PA8572001A1 (no) |
PE (1) | PE20040594A1 (no) |
PL (1) | PL373697A1 (no) |
PT (1) | PT1501804E (no) |
RU (1) | RU2318812C2 (no) |
SI (1) | SI1501804T1 (no) |
TW (1) | TWI278451B (no) |
UY (1) | UY27786A1 (no) |
WO (1) | WO2003091219A1 (no) |
ZA (1) | ZA200408281B (no) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004240649A1 (en) * | 2003-05-19 | 2004-12-02 | Irm, Llc | Immunosuppressant compounds and compositions |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
BRPI0410746A (pt) * | 2003-05-19 | 2006-06-27 | Irm Llc | compostos e composições imunossupressoras |
CN101407471A (zh) | 2003-08-29 | 2009-04-15 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
EP1661881B1 (en) | 2003-08-29 | 2014-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding s1p receptor and pharmaceutical use thereof |
CA2543287A1 (en) * | 2003-10-23 | 2005-05-06 | F.Hoffmann-La Roche Ag | Benzazepine derivatives as mao-b inhibitors |
EP1751111B1 (en) | 2004-03-01 | 2014-12-31 | Actelion Pharmaceuticals Ltd. | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
PT1826197E (pt) | 2004-12-13 | 2012-03-06 | Ono Pharmaceutical Co | Derivado de ácido aminocarboxílico e sua utilização medicinal |
EP1844033B1 (de) * | 2005-01-28 | 2011-07-27 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur herstellung von isochroman und derivaten davon |
AU2006218193A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
WO2007071311A1 (en) | 2005-12-22 | 2007-06-28 | Newron Pharmaceuticals S.P.A. | 2 -phenylethylamino derivatives as calcium and/or sodium channel modulators |
CA2644010A1 (en) * | 2006-03-15 | 2007-09-20 | Actelion Pharmaceuticals Ltd | Tetrahydroisoquinoline derivatives to enhance memory function |
CA2647077A1 (en) | 2006-04-26 | 2007-11-01 | Actelion Pharmaceuticals Ltd | Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists |
KR101220182B1 (ko) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
CN105315204B (zh) * | 2014-07-04 | 2018-02-09 | 中南大学 | 7‑氨基‑1,4‑二氢异喹啉‑3(2h)‑酮衍生物及其合成方法和用途 |
CN105461626B (zh) * | 2015-12-17 | 2018-05-08 | 浙江工业大学 | 芳环或稠杂环联3,4-二氢异喹啉类共轭结构化合物及其应用 |
CN105585527B (zh) * | 2015-12-17 | 2018-06-26 | 浙江工业大学 | 2-(3,4-二氢异喹啉-1(2h)-亚基)乙腈类化合物及其应用 |
US11046675B2 (en) * | 2017-03-27 | 2021-06-29 | Bristol-Myers Squibb Company | Substituted isoquionline derivatives as immunomudulators |
CN114591238B (zh) * | 2022-03-25 | 2022-11-15 | 邦恩泰(山东)生物医药科技集团股份有限公司 | 一种异喹啉类药物中间体的合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6137002A (en) * | 1993-07-22 | 2000-10-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicycle compounds and pharmaceuticals containing them |
US6448269B1 (en) * | 1993-07-22 | 2002-09-10 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
US5679715A (en) | 1995-06-07 | 1997-10-21 | Harris; Richard Y. | Method for treating multiple sclerosis |
CN1116870C (zh) | 1996-03-15 | 2003-08-06 | 萨默塞特药品有限公司 | 司立吉林在制备用于预防或治疗外周神经病的药物中的应用 |
WO2001034172A2 (en) | 1999-11-05 | 2001-05-17 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
-
2003
- 2003-04-14 DE DE60328978T patent/DE60328978D1/de not_active Expired - Lifetime
- 2003-04-14 RU RU2004134575/04A patent/RU2318812C2/ru not_active IP Right Cessation
- 2003-04-14 JP JP2003587782A patent/JP4322685B2/ja not_active Expired - Fee Related
- 2003-04-14 BR BR0309562-2A patent/BR0309562A/pt not_active IP Right Cessation
- 2003-04-14 AT AT03725018T patent/ATE440821T1/de not_active IP Right Cessation
- 2003-04-14 DK DK03725018T patent/DK1501804T3/da active
- 2003-04-14 CN CNB038093766A patent/CN1310890C/zh not_active Expired - Fee Related
- 2003-04-14 PT PT03725018T patent/PT1501804E/pt unknown
- 2003-04-14 NZ NZ535885A patent/NZ535885A/en not_active IP Right Cessation
- 2003-04-14 WO PCT/EP2003/003845 patent/WO2003091219A1/en active Application Filing
- 2003-04-14 ES ES03725018T patent/ES2329354T3/es not_active Expired - Lifetime
- 2003-04-14 MX MXPA04010537A patent/MXPA04010537A/es active IP Right Grant
- 2003-04-14 SI SI200331658T patent/SI1501804T1/sl unknown
- 2003-04-14 KR KR1020047017185A patent/KR100681585B1/ko not_active IP Right Cessation
- 2003-04-14 AU AU2003227614A patent/AU2003227614B2/en not_active Ceased
- 2003-04-14 EP EP03725018A patent/EP1501804B1/en not_active Expired - Lifetime
- 2003-04-14 PL PL03373697A patent/PL373697A1/xx unknown
- 2003-04-14 CA CA2483461A patent/CA2483461C/en not_active Expired - Fee Related
- 2003-04-16 US US10/417,378 patent/US6818774B2/en not_active Expired - Fee Related
- 2003-04-23 PA PA20038572001A patent/PA8572001A1/es unknown
- 2003-04-23 TW TW092109478A patent/TWI278451B/zh not_active IP Right Cessation
- 2003-04-24 PE PE2003000408A patent/PE20040594A1/es not_active Application Discontinuation
- 2003-04-24 GT GT200300095A patent/GT200300095A/es unknown
- 2003-04-24 AR ARP030101412A patent/AR039651A1/es unknown
- 2003-04-25 MY MYPI20031578A patent/MY133527A/en unknown
- 2003-04-28 UY UY27786A patent/UY27786A1/es not_active Application Discontinuation
-
2004
- 2004-10-12 HR HR20040952A patent/HRP20040952A2/hr not_active Application Discontinuation
- 2004-10-13 ZA ZA200408281A patent/ZA200408281B/xx unknown
- 2004-10-18 IL IL16467704A patent/IL164677A0/xx not_active IP Right Cessation
- 2004-10-22 NO NO20044571A patent/NO20044571L/no not_active Application Discontinuation
-
2006
- 2006-01-13 HK HK06100541A patent/HK1080836A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20044571L (no) | Isokinolinderivater | |
SE0202462D0 (sv) | Novel use | |
NO20084845L (no) | 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig | |
NO20082643L (no) | Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft | |
NO20051263L (no) | Ny anvendelse av benzotiazolderivater | |
NO20084872L (no) | 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig | |
WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
NO20051962L (no) | Fenetanolaminderivater for behandling av respiratoriske sykdommer | |
IL150635A0 (en) | Novel use of phenylheteroalkylamine derivatives | |
UA74346C2 (uk) | Похідні амінодикарбонових кислот, їх застосування та лікарський засіб | |
NO20060147L (no) | Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav | |
UA83233C2 (ru) | Замещенный 2-аминотетралин для лечения депрессии | |
NO20055565L (no) | Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO) | |
NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
NO20072089L (no) | Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav | |
NO20061907L (no) | Benzazepinderivater som Mao-B inhibitorer | |
NO20060277L (no) | Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger | |
NO20052699L (no) | 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser. | |
MX2007006744A (es) | Derivados de hidantoina utiles como inhibidores de metaloproteinasa. | |
SE0201837D0 (sv) | Chemical compounds | |
NO20045353L (no) | Orto-substituerte benzosyrederivater for behandling av insulinresistens | |
HUP9801925A1 (hu) | Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására | |
IL150640A0 (en) | Novel use of phenylheteroalkylamine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |